Tissue transglutaminase (tTG) test is used for the diagnosis of certain autoimmune
diseases, which is mostly restricted to celiac disease. In celiac disease, gluten (a protein
found in wheat, barley, rye, and oats) is seen as a foreign invader and is attacked by the
immune system. This is followed by the production of antibodies directed against the
enzyme Tissue Transglutaminase (tTG) (a calcium dependent proteolysis restricting
enzyme), which is normally present in intestines. Immunoglobulin A (IgA) and
immunoglobulin G (IgG) are the antibodies responsible for the autoimmune responses.
These (tTG) IgA and (tTG) IgG can be analyzed for diagnostic purposes. The IgA form of
tTG antibody is more frequently exploited for the diagnosis of celiac disease because it is
synthesized in the small intestine where gluten causes inflammation and irritation in
sensitive people. On the other hand, (tTG) IgG can also be used. Its application in testing is
marked when patient is unable to produce normal IgA as it is less specific to celiac disease.
Traditionally, mucosal biopsies can be performed.
The major factor that propels the Global Tissue Transglutaminase Testing Market is the
increasing prevalence of celiac disease. According to the World Gastroenterology
Organization in 2016, 1% of the total population in western countries was diagnosed with
the celiac disease and the prevalence have substantially increased across the globe.
According to Celiac Disease Foundation in 2016, hospitalization have increased by 600%
from 1998 to 2013 in the U.S. Similar trends in the European countries are observed. All
these factors will boost the global tissue tranglutaminase (tTG) testing market.
Increasing prevalence of autoimmune diseases mainly celiac disease, increasing geriatric
global pool, and increasing investments in the healthcare drive the growth of the market.
Low healthcare expenditure in developing regions, costs considerations, and false positive
diagnosis in geriatric population marked due to conditions such as diarrhoea etc restrain the
growth of the market.
The market is expected to grow at a CAGR of ~17.5% during the forecast period.
Key Players in the Global Tissue Transglutaminase(tTG) Testing Market
Quest Diagnostics Incorporated., SQI Diagnostics, Trinity Biotech, ZEDIRA GmbH,
Demeditec Diagnostics GmbH, ARUP Laboratories, Cell Science Systems, and Bio-Rad
Laboratories, Inc., Pfizer Inc., Celimmune, LLC. And others.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/824 .
Segments
The Global Tissue Transglutaminase Testing Market has been segmented on the basis types
and end users.